Effects of treatment with ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study

Objectives: In the EDITA trial, patients with systemic sclerosis (SSc) and mild pulmonary arterial hypertension (PAH) treated with ambrisentan had a significant decline of pulmonary vascular resistance (PVR) but not of mean pulmonary arterial pressure (mPAP) vs. placebo after 6 months. In the current study, we aimed to assess the long-term effects of continued therapy with ambrisentan vs. standard of care (SoC).